Article
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Molecular pharmacology - 1 Nov 2010
Eich Marcus, Roos Wynand P, Dianov Grigory L, Digweed Martin, Kaina Bernd
Abstract excerpt
Methylating agents are first-line therapeutics for gliomas and malignant melanomas. They attack DNA at various sites, and both O(6)-methylguanine and N-methylated base adducts contribute to the killing response. The mechanism of cellular defense against these agents primarily involves O(6)-methyl...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
